Burning Rock Biotech (BNR) revenue breakdown
By segment, In-hospital business is the largest at 44% of fiscal 2024 revenue; Pharma research and development services grew fastest, 42% a year over 6 years.
By product, Service is the largest at 56% of fiscal 2024 revenue; Product grew fastest, 41% a year over 6 years.
Revenue by segment
Fiscal years, as Burning Rock Biotech reports them in its 10-K filings; fiscal 2024 total $516M.
| Segments | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|---|---|---|---|
| In-hospital business | $33M | $88M | $118M | $165M | $175M | $189M | $224M | 44% |
| Central laboratory business | $161M | $276M | $297M | $319M | $315M | $233M | $176M | 34% |
| Pharma research and development services | $14M | $18M | $15M | $23M | $73M | $116M | $116M | 22% |
Revenue by product
Fiscal years, as Burning Rock Biotech reports them in its 10-K filings; fiscal 2024 total $516M.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|---|---|---|---|
| Service | $180M | $293M | $311M | $342M | $392M | $345M | $291M | 56% |
| Product | $29M | $89M | $119M | $165M | $172M | $192M | $225M | 44% |
Revenue by region
Fiscal years, as Burning Rock Biotech reports them in its 10-K filings; fiscal 2023 total $537M.
| Regions | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|
| PRC | $504M | $553M | $535M | 100% |
| United States | $4M | $10M | $3M | 0% |
Questions
Where does Burning Rock Biotech make its money?
In fiscal 2024, by segment: In-hospital business $224M, Central laboratory business $176M, Pharma research and development services $116M.
From Burning Rock Biotech's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.